These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 16728275)
1. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Ong HT; Timm MM; Greipp PR; Witzig TE; Dispenzieri A; Russell SJ; Peng KW Exp Hematol; 2006 Jun; 34(6):713-20. PubMed ID: 16728275 [TBL] [Abstract][Full Text] [Related]
2. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Anderson BD; Nakamura T; Russell SJ; Peng KW Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464 [TBL] [Abstract][Full Text] [Related]
3. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
4. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536 [TBL] [Abstract][Full Text] [Related]
5. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422 [TBL] [Abstract][Full Text] [Related]
7. Quantitative expression analysis of HHV-6 cell receptor CD46 on cells of human cord blood, peripheral blood and G-CSF mobilised leukapheresis cells. Thulke S; Radonić A; Nitsche A; Siegert W Virol J; 2006 Sep; 3():77. PubMed ID: 16984646 [TBL] [Abstract][Full Text] [Related]
8. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881 [TBL] [Abstract][Full Text] [Related]
9. Is mRNA and protein level of CD46 altered in measles virus vaccine strain S191-infected cells? Hu C; Qi Y; Zhang P; Liu X; Xu Q; Chen X Biochem Biophys Res Commun; 2004 Sep; 322(3):794-802. PubMed ID: 15336534 [TBL] [Abstract][Full Text] [Related]
10. Adaptation of measles virus to polarized epithelial cells: alterations in virus entry and release. Blau DM; Compans RW Virology; 1997 May; 231(2):281-9. PubMed ID: 9168890 [TBL] [Abstract][Full Text] [Related]
11. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576 [TBL] [Abstract][Full Text] [Related]
12. Multiple amino acid substitutions in hemagglutinin are necessary for wild-type measles virus to acquire the ability to use receptor CD46 efficiently. Tahara M; Takeda M; Seki F; Hashiguchi T; Yanagi Y J Virol; 2007 Mar; 81(6):2564-72. PubMed ID: 17182683 [TBL] [Abstract][Full Text] [Related]
13. Wild-type measles virus infection of primary epithelial cells occurs via the basolateral surface without syncytium formation or release of infectious virus. Ludlow M; Rennick LJ; Sarlang S; Skibinski G; McQuaid S; Moore T; de Swart RL; Duprex WP J Gen Virol; 2010 Apr; 91(Pt 4):971-9. PubMed ID: 19923259 [TBL] [Abstract][Full Text] [Related]
14. CD74 is expressed by multiple myeloma and is a promising target for therapy. Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450 [TBL] [Abstract][Full Text] [Related]
15. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Hasegawa K; Nakamura T; Harvey M; Ikeda Y; Oberg A; Figini M; Canevari S; Hartmann LC; Peng KW Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6170-8. PubMed ID: 17062694 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248 [TBL] [Abstract][Full Text] [Related]
17. Rescue and propagation of fully retargeted oncolytic measles viruses. Nakamura T; Peng KW; Harvey M; Greiner S; Lorimer IA; James CD; Russell SJ Nat Biotechnol; 2005 Feb; 23(2):209-14. PubMed ID: 15685166 [TBL] [Abstract][Full Text] [Related]